Today the EU project, TECHGENE, that focuses on developing Next
Generation Sequencing (NGS) diagnostic tools for genetic disorders,
announced that CLC bio has been selected as the software partner for
this project.
The goal of the TECHGENE project is to incorporate the novel massively
parallel sequencing technology in routine diagnostic laboratories for
the improved diagnosis of genetically heterogeneous diseases. To do so,
focus is on a number of model disorders that have shown different
degrees of genetic complexity. Some of these model disorders selected
are hemoglobinopathies, hereditary breast cancer, paraplegias, ataxias,
mental retardation, and sensory disorders including blindness, deafness,
and Usher syndrome.
Chairman of the Dutch Society for clinical genetic laboratory
specialists, Hans Scheffer, PhD, states, "We have decided to
work with CLC bio as their platform for genomics analyses is
best-in-class. Their flexible architecture allows CLC bio to extend
their CLC Genomics Workbench application with features on amplicon
resequencing, making CLC bio the ideal partner for the TECHGENE
consortium. With this user-friendly and integrated solution, our
researchers will eliminate the need for using several methods and
separate software for each different diagnostics method and thereby
greatly enhance our workflows."